Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial.

ABSTRACT:

Objective

To compare the efficacy of Food and Drug Administration recommended dosing of nicardipine versus labetalol for the management of hypertensive patients with signs and/or symptoms (S/S) suggestive of end-organ damage (EOD).

Design

Secondary analysis of the multicentre prospective, randomised CLUE trial.

Setting

13 academic emergency departments in the USA.

Participants

Eligible patients had two systolic blood pressure (SBP) measures ≥180 mm Hg at least 10 min apart, no contraindications to nicardipine or labetalol and predefined S/S suggestive of EOD on arrival.

Interventions

Medications were administered by continuous infusion (nicardipine) or repeat intravenous bolus (labetalol) for a study period of 30 min or until a specified target SBP ±20 m

SUBMITTER: Cannon CM 

PROVIDER: S-EPMC3612758 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature